RN
RNAC.US Cartesian Therapeutics Inc.
- Market cap
- USD 183M
- P/E
- -
- P/B
- 31.26x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RNAC.US undervalued?
Graham numberThe Graham number of Cartesian Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cartesian Therapeutics Inc. fundamental analysis
No fundamental analysis for Cartesian Therapeutics Inc. yet.
Cartesian Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare p…
Full company profileCartesian Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cartesian Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 8.08M | 207K | 903K | 6.68M | 16.6M | 85.1M | 111M | 26.0M | 38.9M | 2.80M | 104K |
| Gross Profit | 8.08M | 207K | 903K | 6.68M | 16.6M | 85.1M | 109M | 26.0M | 38.9M | 2.80M | - |
| Operating Income | -34.7M | -63.8M | -65.0M | -52.5M | -56.8M | -4.60M | 14.5M | -86.4M | -43.9M | -86.7M | -108M |
| EBITDA | -34.2M | -63.4M | -62.9M | -51.8M | -66.6M | -5.63M | 39.1M | -235M | -76.0M | -137M | -39.5M |
| Net Income | -36.2M | -65.3M | -65.3M | -55.4M | -68.9M | -25.7M | 35.4M | -220M | -77.4M | -130M | -49.2M |
| EPS | -124 | -115 | -105 | -44 | -25 | -8.09 | 8.73 | -42 | -3.27 | -5.02 | -1.62 |
| Balance Sheet | |||||||||||
| Total Assets | 89.3M | 101M | 44.5M | 99.6M | 165M | 160M | 166M | 305M | 435M | 296M | 294M |
| Total Liabilities | 34.3M | 49.3M | 49.9M | 91.2M | 183M | 137M | 72.1M | 745M | 442M | 423M | 425M |
| Shareholders' Equity | 55.0M | 51.8M | -5.42M | 8.40M | -18.0M | 22.5M | 93.8M | -440M | -6.80M | -126M | -130M |
| Cash & Short-term Investments | 84.1M | 96.6M | 37.4M | 90.2M | 139M | 128M | 135M | 76.9M | 213M | 125M | 123M |
| Total Debt | 12.0M | 21.0M | 21.4M | 19.3M | 35.3M | 35.3M | 37.9M | 11.0M | 14.0M | 12.7M | 60.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -19.7M | -52.0M | -59.2M | -51.4M | 34.9M | -60.4M | -31.6M | -51.2M | -23.7M | -73.9M | -94.0M |
| Capital Expenditure | 586K | 733K | 884K | 47.0K | 815K | 1.09M | 1.20M | 206K | 9.09M | 5.45M | 987K |
| Free Cash Flow | -20.3M | -52.8M | -60.0M | -51.5M | 34.1M | -61.5M | -32.8M | -51.4M | -32.8M | -79.4M | -95.0M |
| Ratios | |||||||||||
| ROE | -65.9% | -126.1% | - | -659.2% | - | -114.1% | 37.7% | - | - | - | - |
| ROA | -40.5% | -64.6% | -146.9% | -55.6% | -41.6% | -16.1% | 21.3% | -72.0% | -17.8% | -44.0% | -16.7% |
| Net Profit Margin | -448.0% | -31,556.0% | -7,235.4% | -829.0% | -415.0% | -30.2% | 31.9% | -844.9% | -199.0% | -4,658.6% | -47,351.3% |
| Debt to Equity | 0.22x | 0.41x | - | 2.30x | - | 1.57x | 0.40x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cartesian Therapeutics Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 184K | 0.07 | - |
| 2019 | USD 28.0K | 0.02 | - |
| 2018 | - | - | - |
| 2017 | USD 25.5M | 45 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Apr 5, 2024.
Who owns Cartesian Therapeutics Inc.
- Insiders 51.71%
- Institutions 28.80%
- Public & others 19.49%
- Shares outstanding 30.5M
- Free float 11.7M
Top funds holding RNAC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 376K | 1.23% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 367K | 1.20% | 0.00% | Aug 2026 |
| iShares Russell 2000 ETF | 331K | 1.09% | 0.00% | Oct 2026 |
| Janus Henderson Small Cap Gr Alpha ETF | 229K | 0.75% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 147K | 0.48% | +1.91% | Aug 2026 |
| iShares Russell 2000 Value ETF | 94.8K | 0.31% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 76.0K | 0.25% | +1.05% | Sep 2026 |
| Fidelity Extended Market Index | 69.2K | 0.23% | -0.38% | Sep 2026 |
| Bridge Builder Small Cap Fund | 45.0K | 0.15% | +1,137.94% | Oct 2026 |
| iShares Micro-Cap ETF | 40.1K | 0.13% | 0.00% | Oct 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 34.2K | 0.11% | -5.88% | Oct 2026 |
| Schwab Small Cap Index | 32.1K | 0.11% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 25.0K | 0.08% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 24.8K | 0.08% | -0.05% | Sep 2026 |
| Jacob Discovery Fd Instl | 23.5K | 0.08% | +27.03% | Jun 2026 |
| Fidelity Series Total Market Index | 22.4K | 0.07% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 22.1K | 0.07% | -25.58% | Sep 2026 |
| CREF Total Global Stock Account R3 | 19.4K | 0.06% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 18.6K | 0.06% | 0.00% | Aug 2026 |
| Nuveen Small Cap Blend Idx R6 | 17.3K | 0.06% | 0.00% | Sep 2026 |
Top institutions holding RNAC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Squarepoint Ops LLC | 2.25M | 7.39% | +0.72% | Jun 2026 |
| BlackRock Inc | 819K | 2.69% | +36.74% | Jun 2026 |
| Vanguard Capital Management, LLC | 556K | 1.82% | +36.37% | Jun 2026 |
| FMR Inc | 368K | 1.21% | -53.93% | Jun 2026 |
| Geode Capital Management, LLC | 357K | 1.17% | +35.20% | Jun 2026 |
| AQR Capital Management LLC | 356K | 1.17% | +324.25% | Jun 2026 |
| Millennium Management LLC | 310K | 1.02% | +8.99% | Jun 2026 |
| Two Sigma Investments LLC | 296K | 0.97% | +77.09% | Jun 2026 |
| State Street Corp | 249K | 0.82% | +24.40% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 233K | 0.76% | -7.25% | Jun 2026 |
| UBS Group AG | 209K | 0.68% | +52.48% | Jun 2026 |
| Jupiter Topco LLC | 201K | 0.66% | 0.00% | Jun 2026 |
| Privium Fund Management B.V. | 152K | 0.50% | -15.32% | Jun 2026 |
| CM Management, LLC | 120K | 0.39% | +100.00% | Sep 2026 |
| Northern Trust Corp | 106K | 0.35% | +14.90% | Jun 2026 |
| ADAR1 Capital Management LLC | 98.9K | 0.32% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 91.9K | 0.30% | +30.67% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 87.3K | 0.29% | +44.13% | Jun 2026 |
| Diadema Partners LP | 87.1K | 0.29% | 0.00% | Jun 2026 |
| Bank of America Corp | 84.6K | 0.28% | 0.00% | Jun 2026 |
Cartesian Therapeutics Inc. company profile
- Company name
- Cartesian Therapeutics Inc.
- Ticker
- RNAC.US
- Exchange
- USA Stocks
- Listed since
- Jun 22, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 75
- Fiscal year end
- December
- Address
- 7495 New Horizon Way, Frederick, MD, United States, 21703
- Phone
- 301 348 8698
- Website
- cartesiantherapeutics.com
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Cartesian Therapeutics Inc. management
6- Dr. Carsten Brunn Ph.D.President, CEO & Chairman of the Board · born 1971
- Mr. Blaine T. DavisChief Financial Officer · born 1974
- Dr. Emily English Ph.D.Chief Operating Officer · born 1980
- Ms. June SeymourChief Accounting Officer · born 1978
- Mr. Matthew Bartholomae J.D.General Counsel & Secretary
- Dr. Peter G. Traber M.D.Head of R&D · born 1955